Investigational Drug Details
| Drug ID: | D091 |
| Drug Name: | CRV431 |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | 134812041 |
| CasNo: | 1383420-08-3 |
| Repositioning for NAFLD: | No |
| SMILES: | [C@H]([C@@H](CCCCCCNC(=O)C)C)(O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H](N(C(=O)[C@H](N(C(=O)[C@@H](NC1=O)CC)C)C)C)CC(C)C)C(C)C)C)CC(C)C |
| Structure: |
|
| InChiKey: | KBARHGHBFILILC-NGIJKBHDSA-N |
| Molecular Weight: | 1303.784 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | CyP inhibitor |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 completed (NCT04480710) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0161 | NCT04480710 | Phase 2 | Completed | No Results Available | June 23, 2020 | January 10, 2022 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A09115 | 31868526 | Expert Opin Investig Drugs | Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH). | Details |
| A29577 | 33844557 | Org Lett | Semisynthesis of CRV431. | Details |
| A31006 | 31406003 | J Pharmacol Exp Ther | A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models. | Details |
| A48624 | 32764799 | PLoS One | Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice. | Details |